Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma

BACKGROUND: Nivolumab, a programmed death-1 checkpoint inhibitor, demonstrated encouraging overall survival in uncontrolled studies in previously treated patients with advanced renal cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in renal cell carcinoma...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Main Authors: Motzer, Robert J., Escudier, Bernard, McDermott, David F., George, Saby, Hammers, Hans J., Srinivas, Sandhya, Tykodi, Scott S., Sosman, Jeffrey A., Procopio, Giuseppe, Plimack, Elizabeth R., Castellano, Daniel, Choueiri, Toni K., Gurney, Howard, Donskov, Frede, Bono, Petri, Wagstaff, John, Gauler, Thomas C., Ueda, Takeshi, Tomita, Yoshihiko, Schutz, Fabio A., Kollmannsberger, Christian, Larkin, James, Ravaud, Alain, Simon, Jason S., Xu, Li-An, Waxman, Ian M., Sharma, Padmanee
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5719487/
https://ncbi.nlm.nih.gov/pubmed/26406148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1510665
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares